InxMed Co., Ltd, a clinical-stage biotechnological company, pioneering therapies to transform cancer treatment, released latest clinical data from a Phase Ib/II clinical trial (NCT06166836; ...

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...